Bruker Corporation (BRKR)
NASDAQ: BRKRIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BRKR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.62B
- Forward P/E
- 23.25
- EPS (TTM)
- -$1.10
- Dividend yield
- 0.09% ($0.05)
- Ex-dividend date
- Dec 21, 2026
- 52-week range
- 32.37 – 68.98
- Day range
- 56.13 – 61.10
- Volume / Avg
- 2.25M / 2.32M
- Beta
- —
- Shares outstanding
- 152.72M
52-week range
BRKR stock today
On Nov 20, BRKR ended the session at $56.46, shedding $5.64 (9.08%), versus the S&P 500's 3.70% decline. Shares are 18.2% below their 52-week high of $68.98, set on Nov 4, 2026 and 74.4% above the 52-week low of $32.37, in the middle of the past year's range. BRKR is up 19.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 19.4%.
Bruker has posted a net loss over the last twelve months (EPS of -$1.10), so its P/E ratio is not meaningful. Bruker pays an annual dividend of $0.05 per share, a 0.09% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Bruker
Company profileBruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Frank H. Laukien Ph.D.
- Headquarters
- Billerica, MA
- Employees
- 11,085
- Website
- bruker.com
Financial highlights
Full financialsIn fiscal 2025, Bruker generated $3.44 billion in revenue, up 2.1% from fiscal 2024, its 5th consecutive year of revenue growth. Bruker reported a net loss of $8.6 million, compared with net income of $113.1 million a year earlier. Gross margin was 45.9% (down from 49.0%) and operating margin 2.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.44B | $3.37B | $2.96B | $2.53B | $2.42B |
| Growth | +2.08% | +13.56% | +17.14% | +4.67% | +21.66% |
| Net income | $-8.60M | $113.10M | $427.20M | $296.60M | $277.10M |
| EPS (diluted) | $-0.15 | $0.76 | $2.90 | $1.99 | $1.81 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$68.00+20.44%
- Strong buy 1
- Buy 5
- Hold 6
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.45 vs $0.42
- Surprise
- +7.14%
Dividends
Dividend history- Annual dividend
- $0.05
- Dividend yield
- 0.09%
- Last payment
- $0.05
- Ex-dividend date
- Dec 21, 2026
- Pay date
- Jan 7, 2027
BRKR news
All BRKR news- Bruker a new Sector Perform at RBC as gains 'appear in the rearview'Seeking Alpha
- Here's Why Bruker (BRKR) is a Strong Momentum StockNasdaq
- Bruker Corporation Appoints Eicke Latz MD PhD to Board of Directors and Declares Quarterly Cash Dividend of $0.05 per shareNasdaq
- Should You Continue to Retain Bruker Stock in Your Portfolio?NasdaqBRKR, IDXX, GMED, PAHC
- Bruker's Preferred Stock, Series A Ex-Dividend Reminder - 11/13/26Nasdaq
- Bruker Corporation 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
- Bruker: Five Quarters Of Orders Are Still Waiting To Show Up In RevenueSeeking Alpha
- Bruker Corporation Reorganizes Reportable Segments Effective July 1, 2026Nasdaq
Bruker peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIOBio-Rad Laboratories Inc. Class A | 358.90 | -2.34% | $9.65B | vs BRKR |
| AVTRAvantor Inc. | 14.84 | -1.85% | $10.06B | vs BRKR |
| TXG10x Genomics Inc. Class A | 51.80 | -9.72% | $6.81B | vs BRKR |
| ALMRAlamar Biosciences Inc. | 26.48 | -7.67% | $1.84B | vs BRKR |
| RVTYRevvity Inc. | 145.22 | -4.20% | $16.21B | vs BRKR |
| CTKBCytek Biosciences Inc. | 6.12 | -3.16% | $800.40M | vs BRKR |
| PACBPacific Biosciences of California Inc. | 1.63 | -7.39% | $508.95M | vs BRKR |
| NAUTNautilus Biotechnology Inc. | 2.12 | -2.30% | $270.03M | vs BRKR |
Indexes, lists and sector
Bruker stock FAQ
What is Bruker's stock price today?
BRKR last traded at $56.46 as of Nov 20, 4:00 PM EST, down 9.08% on the day. Prices are delayed at least 15 minutes.
Does Bruker pay a dividend?
Yes. Bruker pays $0.05 per share annually, a 0.09% yield. The most recent dividend of $0.05 had an ex-dividend date of Dec 21, 2026.
Who is Bruker's CEO?
Dr. Frank H. Laukien Ph.D. is the chief executive officer of Bruker Corporation, which has about 11,085 employees.
What is the BRKR 52-week high?
The 52-week high for BRKR is $68.98 and the 52-week low is $32.37. The stock is currently 18.2% below its high.